TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: APERTO CVS PMCF Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients age \>18, no pregnant women, able to perform fup visits, life expectancy \> 12 months~* Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic stenosis (de novo or restenosis) of the central veins with significant (\>50%) stenosis and diameter~* The target lesion consists of one or more lesions with a target lesion length of less than or equal to 100 mm~* The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in angiographic or ultrasound evaluation);~* If there are other non-target lesions, then non-target lesions must be successfully cured with a not drug coated balloon before treating the target lesion;~Exclusion Criteria:~* Patients with CVS observed and estimated as nonsignificant (\< 50% stenosis) or a vessel \> 12 mm in diameter by visual estimation;~* the patient is now participating in another clinical trial to evaluate drug or medical device;~* patient enrolled for this trial before;~* prenatal pregnancy test result for women of childbearing potential is non-negative, Lactating woman;~* patients, who underwent major surgical procedures (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study;~* patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within 30 days after enrolment;~* central veins lesions have been already treated with DCB before~* presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in central veins~* patients allergic or intolerant to paclitaxel, or contrast media;~* patients whose life expectancy is less than 1 year~* presence of Thrombus in central veins~* tumor compression~* thoracic inlet syndrome~* patients implanted with pacing or cardioverter devices with leads~* any other central line within the target lesion~* Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APERTO OTW DCB (Type: None): Dialysis patients treated with APERTO OTW following (re)stenosis of central veins

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: First in Man Aer-O-Scope

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers between 18 and 65 years of age.~* Sign informed consent.~Exclusion Criteria:~* Subjects with any known GI related symptoms complaints or GI diseases.~* Subjects with cancer or other life threatening diseases or conditions.~* Pregnant women.~* Subjects who underwent any abdominal surgery.~* Morbid Obesity (BMI \> 40).~* Drug abuse or alcoholism.~* Bed-ridden subject.~* Inadequate communication with the subject.~* Subjects under custodial care.~* Participation in any clinical study within the last 30 days.~* Subjects with known cardiovascular and pulmonary diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- single arm (Type: EXPERIMENTAL): single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Do Hydrophilic Catheters Decrease Pain and Discomfort of a Patient During Urodynamic Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients~2. Age 18 and above~3. Scheduled and consented for urodynamic study~4. Able to sign an informed consent and agree to be included to a study.~Exclusion Criteria:~1. indwelling catheter~2. use of pain killers in 24 hours prior to urodynamic study~3. persistent abdominal, perineal or pelvic pain or discomfort prior to a study~4. prior or suspected urethral stricture~5. urinary tract infection~6. positive asymptomatic urine culture prior to urodynamic study~7. scheduled for a transurethral cystoscopic examination at the same day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Female Speedicath nelathon (Type: None): Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
- Female nelathon (Type: None): Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
- Male Speedicath tiemann (Type: None): Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
- Male tiemann (Type: None): Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the RA0056 study (Week 12 Visit)~* Subject must have maintained their stable dose (and route) of methotrexate (MTX) between 12.5 to 25mg/week in RA0056, and plan to maintain this same dose and route of administration for at least 12 weeks~* Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (either oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is not considered an acceptable method of contraception for this study~* Female subjects of childbearing potential must agree to use 2 methods of adequate contraception during the study and for 6 months (24 weeks) after their last CDP6038 (olokizumab) dose~* Male subjects must agree to ensure that they or their female partner(s) use adequate contraception during the study and for 12 weeks after the subject receives their last dose of CDP6038 (olokizumab)~Exclusion Criteria:~* Subject has an ongoing serious adverse event from the RA0056 study~* Female subject of childbearing potential has a positive pregnancy test at Week 12 in Study RA0056 or plans to become pregnant during the study or within 6 months (24 weeks) following their last dose of study medication~* Subject has evidence of active or latent tuberculosis~* Subject is receiving any biologic response modifier or synthetic disease-modifying antirheumatic drug other than MTX~* Subject has an alcohol consumption of more than 1 unit per weekday. One unit equals 1 glass of beer or lager (\~330mL), a glass of wine (125mL), or a measure of spirits/hard liquor (25mL)~* Subject with any other condition in RA0056 (eg, clinically significant laboratory values, frequent adverse events) which in the Investigator's or Sponsor's judgment would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP6038 (olokizumab) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, histologically diagnosed high-grade serous~* Platinum-resistant disease (relapsing within 3-6 months after completion of initial platinum-based treatment). Patients progressing at any time on or after ≥ 2nd platinum-based therapy are eligible.~* Received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy~* Evidence of progressive disease~* Measurable disease (RECIST v1.1) with at least one non-target lesion accessible by image-guided biopsy. No single lesion may be larger than 4 cm in diameter.~* Completed pre-treatment tumor biopsy and willing to undergo on-treatment tumor biopsy~* ECOG 0-1~* Live expectancy ≥ 6 months~* Meet protocol-specified laboratory requirements~Key Exclusion Criteria:~* Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy~* Prior receipt of survivin-based vaccines/therapy, immune checkpoint inhibitors, IDO inhibitor, or cell-based therapy~* Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum~* Clinical ascites~* Concurrent second malignancy other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission~* GI condition that might limit absorption of oral agents~* Recent history of thyroiditis~* History of autoimmune disease requiring treatment within the last two years (except paraneoplastic syndrome, vitiligo, or diabetes)~* History of bowel obstruction related to the disease~* Presence of a serious acute infection or chronic infection~* Uncontrolled concurrent illness or history of significant cardiac or pulmonary disfunction~* Myocardial infarction or cerebrovascular event within past 6 months~* Known central nervous system (CNS) or leptomeningeal metastasis (brain metastases)~* Clinically significant illness or major surgery within past 28 days or anticipated need for major surgery during study treatment~* Ongoing treatment with steroid therapy or other immunosuppressive~* Receipt of live attenuated vaccines~* Edema or lymphedema in the lower limbs \> grade 2~* Acute or chronic skin and/or microvascular disorders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVP-S + CPA (Type: EXPERIMENTAL): All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mission is Remission®: How Can a Disease Self-management Website Change Care?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric IBD patients (approximately 100 patients randomly assigned to the Mission is Remission® group or the wait-list control group) and one of their parents/primary caregivers;~2. Patient is between 12-18 years of age, inclusive;~3. Meets screening criteria for low self-efficacy;~4. Signed informed consent from parent and assent from patient.~Exclusion Criteria:~1. Not English speaking;~2. Children with cognitive impairment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Mission is Remission® Group (Type: EXPERIMENTAL): Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
- Control Group (Type: NO_INTERVENTION): Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the colon that is unlikely to respond to existing therapy and for which no curative therapy exists~* Metastatic or unresectable disease~* Measurable disease by CT scan or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal failure~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors may be admitted earlier)~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agent allowed~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Sepsis \[ ≥2 Systemic Inflammatory Response Syndrome (SIRS) Criteria AND known or suspected infection\]~* Muscle weakness \[Medical Research Council sum score \<48/60 or handgrip strength \<11 kg in men and \<7 kg in women\]~* Obey Commands \[Score for DeJonghe Awakening Score of ≥3/5\]~Exclusion Criteria:~* Severe renal insufficiency \[Creatinine Clearance \<30 mL/min - or receiving dialysis\]~* Acute infectious or auto-immune hepatitis, acute liver failure or a history of cirrhosis without liver transplant~* History of psychosis~* Bradycardia, or 2nd or 3rd degree Atrio-Ventricular block without pacemaker~* History of valvular heart disease without valve replacement~* History of priapism~* Pre-existing cognitive impairment~* Receiving drugs with serotonergic effects and/or CYP2D6 substrates which cannot be substituted stopped or titrated.~* Receiving Sulfonylurea medication at the time of the study~* Prior neuromuscular or central nervous system disease, including pre-existing neuropathy~* Inability to perform study's muscle strength assessments based on patient's baseline status prior to hospital admission~* Unable to receive, or unlikely to absorb study drug (e.g. bowel obstruction, ischemia, or infarction; short gut syndrome)~* Body mass index \>40~* Patient not expected to survive \>4 days~* Pregnancy or lactation~* Allergy to lorcaserin or lorcaserin taken in the prior 7 days~* Enrolled in another interventional drug or physical rehabilitation trial~* Physician declines for patient to be enrolled~* Patient or proxy declines consent~* Unable to reach proxy for consent~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
- Control (Type: PLACEBO_COMPARATOR): Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Has received intraosseous vascular access at the proximal humerus insertion site via EZ-IO as standard of care~* Requires CT examination with contrast media delivery via proximal humerus intraosseous catheter, as standard of care~* Cognitively and physically able to give written consent to participate in the study~Exclusion Criteria:~* Fracture in target bone, or significant trauma to the site~* Excessive tissue and/or absence of adequate anatomical landmarks in target bone~* Infection in target area~* IO insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone~* Allergy to contrast media~* Imprisoned~* Pregnant~* Requires English language translation other than Spanish~* Has received IO access with an IO catheter other than the EZ-IO system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have benign intracranial hypertension.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound Testing (Type: OTHER): Single arm with all patients getting measurements of axial length and central corneal thickness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients 18 years of age or older admitted to the intensive care units of St. Boniface General Hospital with a diagnosis of acute pulmonary blastomycosis requiring mechanical ventilation.~Exclusion Criteria:~* The patient's data will be excluded if they die within 3 days of hospital admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amphotericin-B and Voriconazole (Type: OTHER): Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. \~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient 18 years of age or older~* Recipient with chronic end-stage liver disease~* Deceased donor liver transplant~* Recipient capable of providing written informed consent~* Whole organ graft from donors aged 60 years or older~Exclusion Criteria:~* Fulminant liver failure~* Objection by any other member of the retrieval team~* Split-liver grafts~* Donor that has received total parenteral nutrition within 24hr of organ retrieval Donors from whom the pancreas and/or small bowel are also being retrieved

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
- 2 (Type: NO_INTERVENTION): Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues